Houston, Texas and Tuebingen, Germany, August 21, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its...
Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse
EMBL Ventures portfolio company Luxendo acquired by Bruker
Successful exit just 1.5 years after the Company’s founding proves investment rationale
Arsanis Completes $45.5 Million Series D Financing
Company set to advance pipeline of monoclonal antibodies for serious infectious diseases, including lead Phase 2 program ASN100 for the prevention of Staphylococcus aureus pneumonia in high-risk ICU patients